T Cell Receptor Vβ Staining Identifies the Malignant Clone in Adult T cell Leukemia and Reveals Killing of Leukemia Cells by Autologous CD8+ T cells

PLoS Pathogens

Volumn 12, Issue 11, 2016, Pages

  Rowan, Aileen G ^a   Witkover, Aviva ^a   Melamed, Anat ^a   Tanaka, Yuetsu ^b   Cook, Lucy B M ^a   Fields, Paul ^c   Taylor, Graham P ^a   Bangham, Charles R M ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF THE RYUKYUS   (Japan)

^c GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

T LYMPHOCYTE RECEPTOR BETA CHAIN; VASCULAR CELL ADHESION MOLECULE 1; LYMPHOCYTE ANTIGEN RECEPTOR; TAX PROTEIN;

ARTICLE; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; CELL SURVIVAL; CONTROLLED STUDY; CYTOLYSIS; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOGENICITY; INTRACELLULAR KILLING; PROTEIN EXPRESSION; T CELL LEUKEMIA; ADULT; AGED; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; FEMALE; IMMUNOLOGY; MALE; MIDDLE AGED;

ADULT; AGED; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; FLOW CYTOMETRY; GENE PRODUCTS, TAX; HUMANS; LEUKEMIA-LYMPHOMA, ADULT T-CELL; MALE; MIDDLE AGED; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; T-LYMPHOCYTES, CYTOTOXIC;

EID: 85002388890     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1006030     Document Type: Article

References (51)

1. Shimoyama M, Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984–87). Br J Haematol. 1991;79: 428–437. 1751370
2. Katsuya H, Ishitsuka K, Utsunomiya A, Hanada S, Eto T, Moriuchi Y, et al. Treatment and survival among 1594 patients with ATL. Blood. 2015;126: 2570–7. doi: 10.1182/blood-2015-03-63248926361794
3. Utsunomiya A, Choi I, Chihara D, Seto M, Recent advances in the treatment of adult T-cell leukemia-lymphomas. Cancer Sci. 2015;106: 344–351. doi: 10.1111/cas.1261725613789
4. Hermine O, Bouscary D, Gessain A, Turlure P, Leblond V, Franck N, et al. Brief report: treatment of adult T-cell leukemia-lymphoma with zidovudine and interferon alfa. N Engl J Med. 1995;332: 1749–51. doi: 10.1056/NEJM1995062933226047760891
5. Gill P, Harrington W, Kaplan M, Ribeiro R, Bennett J, Liebman H, et al. Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine. N Engl J Med. 1995;332: 1744–1748. doi: 10.1056/NEJM1995062933226037760890
6. Hodson A, Crichton S, Montoto S, Mir N, Matutes E, Cwynarski K, et al. Use of Zidovudine and Interferon Alfa With Chemotherapy Improves Survival in Both Acute and Lymphoma Subtypes of Adult T-Cell Leukemia/Lymphoma. J Clin Oncol. 2011;29: 4696–4701. doi: 10.1200/JCO.2011.35.557822042945
7. Bazarbachi A, Plumelle Y, Ramos JC, Tortevoye P, Otrock Z, Taylor G, et al. Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia/lymphoma showing improved survival in the leukemic subtypes. J Clin Oncol. 2010;28: 4177–4183. doi: 10.1200/JCO.2010.28.066920585095
8. Ishii T, Ishida T, Utsunomiya A, Inagaki A, Yano H, Komatsu H, et al. Defucosylated humanized anti-CCR4 monoclonal antibody KW-0761 as a novel immunotherapeutic agent for adult T-cell leukemia/lymphoma. Clin Cancer Res. 2010;16: 1520–31. doi: 10.1158/1078-0432.CCR-09-269720160057
9. Ishida T, Joh T, Uike N, Yamamoto K, Utsunomiya A, Yoshida S, et al. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study. J Clin Oncol. 2012;30: 837–42. doi: 10.1200/JCO.2011.37.347222312108
10. Ishida T, Jo T, Takemoto S, Suzushima H, Uozumi K, Yamamoto K, et al. Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: a randomized phase II study. Br J Haematol. 2015;169: 672–82. doi: 10.1111/bjh.1333825733162
11. Igakura T, Stinchcombe JC, Goon PKC, Taylor GP, Weber JN, Griffiths GM, et al. Spread of HTLV-I between lymphocytes by virus-induced polarization of the cytoskeleton. Science. 2003;299: 1713–6. doi: 10.1126/science.108011512589003
12. Gillet NA, Malani N, Melamed A, Gormley N, Carter R, Bentley D, et al. The host genomic environment of the provirus determines the abundance of HTLV-1-infected T-cell clones. Blood. 2011;117: 3113–22. doi: 10.1182/blood-2010-10-31292621228324
13. Matsuoka M, Yasunaga J, Human T-cell leukemia virus type 1: replication, proliferation and propagation by Tax and HTLV-1 bZIP factor. Curr Opin Virol. 2013;3: 684–91. doi: 10.1016/j.coviro.2013.08.01024060211
14. Cook LB, Rowan AG, Melamed A, Taylor GP, Bangham CRM, HTLV-1-infected T cells contain a single integrated provirus in natural infection. Blood. 2012;120: 3488–90. doi: 10.1182/blood-2012-07-44559322955925
15. Cook LB, Melamed A, Niederer H, Valganon M, Laydon D, Foroni L, et al. The role of HTLV-1 clonality, proviral structure, and genomic integration site in adult T-cell leukemia/lymphoma. Blood. 2014;123: 3925–31. doi: 10.1182/blood-2014-02-55360224735963
16. Melamed A, Laydon DJ, Gillet NA, Tanaka Y, Taylor GP, Bangham CRM, Genome-wide determinants of proviral targeting, clonal abundance and expression in natural HTLV-1 infection. PLoS Pathog. 2013;9: e1003271. doi: 10.1371/journal.ppat.100327123555266
17. Kataoka K, Nagata Y, Kitanaka A, Shiraishi Y, Shimamura T, Yasunaga J, et al. Integrated molecular analysis of adult T cell leukemia/lymphoma. Nat Genet. 2015;47: 1304–15. doi: 10.1038/ng.341526437031
18. Nakagawa M, Schmitz R, Xiao W, Goldman CK, Xu W, Yang Y, et al. Gain-of-function CCR4 mutations in adult T cell leukemia/lymphoma. J Exp Med. 2014;211: 2497–505. doi: 10.1084/jem.2014098725488980
19. Nishimura S, Asou N, Suzushima H, Okubo T, Fujimoto T, Osato M, et al. p53 gene mutation and loss of heterozygosity are associated with increased risk of disease progression in adult T cell leukemia. Leukemia. 1995;9: 598–604. 7723391
20. Pancewicz J, Taylor JM, Datta A, Baydoun HH, Waldmann T a, Hermine O, et al. Notch signaling contributes to proliferation and tumor formation of human T-cell leukemia virus type 1-associated adult T-cell leukemia. Proc Natl Acad Sci U S A. 2010;107: 16619–24. doi: 10.1073/pnas.101072210720823234
21. Asquith B, Bangham CRM, How does HTLV-I persist despite a strong cell-mediated immune response?Trends Immunol. 2008;29: 4–11. doi: 10.1016/j.it.2007.09.00618042431
22. Asquith B, Zhang Y, Mosley AJ, de Lara CM, Wallace DL, Worth A, et al. In vivo T lymphocyte dynamics in humans and the impact of human T-lymphotropic virus 1 infection. Proc Natl Acad Sci U S A. 2007;104: 8035–8040. doi: 10.1073/pnas.060883210417483473
23. Jeffery KJ, Usuku K, Hall SE, Matsumoto W, Taylor GP, Procter J, et al. HLA alleles determine human T-lymphotropic virus-I (HTLV-I) proviral load and the risk of HTLV-I-associated myelopathy. Proc Natl Acad Sci U S A. 1999;96: 3848–53. 10097126
24. Hasegawa H, Sawa H, Lewis MJ, Orba Y, Sheehy N, Yamamoto Y, et al. Thymus-derived leukemia-lymphoma in mice transgenic for the Tax gene of human T-lymphotropic virus type I. Nat Med. 2006;12: 466–72. doi: 10.1038/nm138916550188
25. Satou Y, Yasunaga J, Yoshida M, Matsuoka M, HTLV-I basic leucine zipper factor gene mRNA supports proliferation of adult T cell leukemia cells. Proc Natl Acad Sci U S A. 2006;103: 720–5. doi: 10.1073/pnas.050763110316407133
26. Macnamara A, Rowan A, Hilburn S, Kadolsky U, Fujiwara H, Suemori K, et al. HLA class I binding of HBZ determines outcome in HTLV-1 infection. PLoS Pathog. 2010;6: e1001117. doi: 10.1371/journal.ppat.100111720886101
27. Mitobe Y, Yasunaga J-I, Furuta R, Matsuoka M, HTLV-1 bZIP Factor RNA and Protein Impart Distinct Functions on T-cell Proliferation and Survival. Cancer Res. 2015;75: 4143–52. doi: 10.1158/0008-5472.CAN-15-094226383166
28. Arnulf B, Thorel M, Poirot Y, Tamouza R, Boulanger E, Jaccard A, et al. Loss of the ex vivo but not the reinducible CD8+ T-cell response to Tax in human T-cell leukemia virus type 1-infected patients with adult T-cell leukemia/lymphoma. Leukemia. 2004;18: 126–32. doi: 10.1038/sj.leu.240317614574331
29. Kozako T, Arima N, Toji S, Masamoto I, Akimoto M, Hamada H, et al. Reduced frequency, diversity, and function of human T cell leukemia virus type 1-specific CD8+ T cell in adult T cell leukemia patients. J Immunol. 2006;177: 5718–26. 17015761
30. Toulza F, Heaps A, Tanaka Y, Taylor GP, Bangham CRM, High frequency of CD4+FoxP3+ cells in HTLV-1 infection: inverse correlation with HTLV-1-specific CTL response. Blood. 2008;111: 5047–53. doi: 10.1182/blood-2007-10-11853918094326
31. Kozako T, Yoshimitsu M, Fujiwara H, Masamoto I, Horai S, White Y, et al. PD-1/PD-L1 expression in human T-cell leukemia virus type 1 carriers and adult T-cell leukemia/lymphoma patients. Leukemia. 2009;23: 375–82. doi: 10.1038/leu.2008.27218830259
32. Jinnohara T, Tsujisaki M, Sasaki S, Hinoda Y, Imai K, Cytotoxic activity in a case of adult T-cell leukemia/lymphoma with spontaneous regression. Int J Hematol. 1997;65: 293–8. 9114601
33. Tanaka Y, Nakasone H, Yamazaki R, Wada H, Ishihara Y, Kawamura K, et al. Long-term persistence of limited HTLV-I Tax-specific cytotoxic T cell clones in a patient with adult T cell leukemia/lymphoma after allogeneic stem cell transplantation. J Clin Immunol. 2012;32: 1340–52. doi: 10.1007/s10875-012-9729-522763862
34. Harashima N, Kurihara K, Utsunomiya A, Tanosaki R, Hanabuchi S, Masuda M, et al. Graft-versus-Tax response in adult T-cell leukemia patients after hematopoietic stem cell transplantation. Cancer Res. 2004;64: 391–9. 14729650
35. Rowan AG, Bangham CRM, Is There a Role for HTLV-1-Specific CTL in Adult T-Cell Leukemia/Lymphoma?Leuk Res Treatment. 2012;2012: 391953. doi: 10.1155/2012/39195323259066
36. Manivannan K, Rowan AG, Tanaka Y, Taylor GP, Bangham CRM, Ross SR, CADM1/TSLC1 Identifies HTLV-1-Infected Cells and Determines Their Susceptibility to CTL-Mediated Lysis. PLOS Pathog. 2016;12: e1005560. doi: 10.1371/journal.ppat.100556027105228
37. Sasaki H, Nishikata I, Shiraga T, Akamatsu E, Fukami T, Hidaka T, et al. Overexpression of a cell adhesion molecule, TSLC1, as a possible molecular marker for acute-type adult T-cell leukemia. Blood. 2005;105: 1204–13. doi: 10.1182/blood-2004-03-122215471956
38. Ishida T, Utsunomiya A, Iida S, Inagaki H, Takatsuka Y, Kusumoto S, et al. Clinical significance of CCR4 expression in adult T-cell leukemia/lymphoma: its close association with skin involvement and unfavorable outcome. Clin Cancer Res. 2003;9: 3625–34. 14506150
39. Kobayashi S, Tian Y, Ohno N, Yuji K, Ishigaki T, Isobe M, Vartanian J-P, et al. The CD3 versus CD7 plot in multicolor flow cytometry reflects progression of disease stage in patients infected with HTLV-I. PLoS One. 2013;8: e53728. doi: 10.1371/journal.pone.005372823349737
40. Karube K, Ohshima K, Tsuchiya T, Yamaguchi T, Kawano R, Suzumiya J, et al. Expression of FoxP3, a key molecule in CD4CD25 regulatory T cells, in adult T-cell leukaemia/lymphoma cells. Br J Haematol. 2004;126: 81–4. doi: 10.1111/j.1365-2141.2004.04999.x15198736
41. Tian Y, Kobayashi S, Ohno N, Isobe M, Tsuda M, Zaike Y, et al. Leukemic T cells are specifically enriched in a unique CD3(dim) CD7(low) subpopulation of CD4(+) T cells in acute-type adult T-cell leukemia. Cancer Sci. 2011;102: 569–77. doi: 10.1111/j.1349-7006.2010.01833.x21205081
42. Reinhold U, Abken H, CD4+ CD7- T cells: a separate subpopulation of memory T cells?J Clin Immunol. 1997;17: 265–71. 9258765
43. Kobayashi S, Watanabe E, Ishigaki T, Ohno N, Yuji K, Nakano K, et al. Advanced human T-cell leukemia virus type 1 carriers and early-stage indolent adult T-cell leukemia-lymphoma are indistinguishable based on CADM1 positivity in flow cytometry. Cancer Sci. 2015;106: 598–603. doi: 10.1111/cas.1263925703103
44. van den Beemd R, Boor PP, van Lochem EG, Hop WC, Langerak AW, Wolvers-Tettero IL, et al. Flow cytometric analysis of the Vbeta repertoire in healthy controls. Cytometry. 2000;40: 336–45. 10918284
45. Hanley JA, McNeil BJ, The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 1982;143: 29–36. doi: 10.1148/radiology.143.1.70637477063747
46. Asquith B, Mosley AJ, Barfield A, Marshall SEF, Heaps A, Goon P, et al. A functional CD8+ cell assay reveals individual variation in CD8+ cell antiviral efficacy and explains differences in human T-lymphotropic virus type 1 proviral load. J Gen Virol. 2005;86: 1515–23. doi: 10.1099/vir.0.80766-015831965
47. Hanon E, Hall S, Taylor GP, Saito M, Davis R, Tanaka Y, et al. Abundant Tax protein expression in CD4 + T cells infected with human T-cell lymphotropic virus type I (HTLV-I) is prevented by cytotoxic T lymphocytes. Blood. 2000;95: 1386–1392. 10666215
48. Boles KS, Barchet W, Diacovo T, Cella M, Colonna M, The tumor suppressor TSLC1/NECL-2 triggers NK-cell and CD8+ T-cell responses through the cell-surface receptor CRTAM. Blood. 2005;106: 779–86. doi: 10.1182/blood-2005-02-081715811952
49. Sugata K, Yasunaga J-I, Mitobe Y, Miura M, Miyazato P, Kohara M, et al. Protective effect of cytotoxic T lymphocytes targeting HTLV-1 bZIP factor. Blood. 2015;126: 1095–105. doi: 10.1182/blood-2015-04-64111826063164
50. Rowan AG, Suemori K, Fujiwara H, Yasukawa M, Tanaka Y, Taylor GP, et al. Cytotoxic T lymphocyte lysis of HTLV-1 infected cells is limited by weak HBZ protein expression, but non-specifically enhanced on induction of Tax expression. Retrovirology. 2014;11: 116. doi: 10.1186/s12977-014-0116-625499803
51. Gini C, Cuppini C, Variabilita e Mutuabilita. Contributo allo Studio delle Distribuzioni e delle Relazioni Statistiche. Bologna, Italy; 1912.